Blinatumoab公司
美罗华
医学
移植后淋巴增生性疾病
造血干细胞移植
免疫学
爱泼斯坦-巴尔病毒
肿瘤科
移植
内科学
淋巴瘤
免疫系统
病毒
CD19
作者
Shulian Chen,Licai An,Jie Han,Xiao‐Hui Zheng,Xiaoyu Zhang,Gang Li,Ying Zhang,Wenbin Cao,Mengnan Lv,Donglin Yang,Erlie Jiang,Aiming Pang,Sizhou Feng
标识
DOI:10.1016/j.trim.2023.101895
摘要
Post-transplant lymphoproliferative disorder (PTLD) is a condition in which patients experience the unrestrained proliferation of B cells as a consequence of impaired immune surveillance, almost always as a consequence of Epstein–Barr virus (EBV) infection. It remains one of the most serious potential complications that patients can experience after undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). While treatment with rituximab can significantly improve the prognosis of individuals with EBV-PTLD, those patients in whom rituximab fails to provide appreciable clinical benefit generally exhibit very poor outcomes. In the present report, we describe the case of an EBV-PTLD patient who was successfully treated with blinatumomab and received maintenance therapy consisting of venetoclax combined with azacytidine (AZA). The present case highlights the potential utility of blinatumomab as an effective treatment option for individuals with high-risk EBV-PTLD, although further explanation of the optimal dosing and treatment duration is warranted in the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI